eLife (Jul 2020)

The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling

  • Amy A Worth,
  • Rosemary Shoop,
  • Katie Tye,
  • Claire H Feetham,
  • Giuseppe D'Agostino,
  • Garron T Dodd,
  • Frank Reimann,
  • Fiona M Gribble,
  • Emily C Beebe,
  • James D Dunbar,
  • Jesline T Alexander-Chacko,
  • Dana K Sindelar,
  • Tamer Coskun,
  • Paul J Emmerson,
  • Simon M Luckman

DOI
https://doi.org/10.7554/eLife.55164
Journal volume & issue
Vol. 9

Abstract

Read online

The cytokine, GDF15, is produced in pathological states which cause cellular stress, including cancer. When over expressed, it causes dramatic weight reduction, suggesting a role in disease-related anorexia. Here, we demonstrate that the GDF15 receptor, GFRAL, is located in a subset of cholecystokinin neurons which span the area postrema and the nucleus of the tractus solitarius of the mouse. GDF15 activates GFRALAP/NTS neurons and supports conditioned taste and place aversions, while the anorexia it causes can be blocked by a monoclonal antibody directed at GFRAL or by disrupting CCK neuronal signalling. The cancer-therapeutic drug, cisplatin, induces the release of GDF15 and activates GFRALAP/NTS neurons, as well as causing significant reductions in food intake and body weight in mice. These metabolic effects of cisplatin are abolished by pre-treatment with the GFRAL monoclonal antibody. Our results suggest that GFRAL neutralising antibodies or antagonists may provide a co-treatment opportunity for patients undergoing chemotherapy.

Keywords